Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

NCT00950911 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Bone Metastases in Subjects With Advanced Breast Cancer
Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Interventions

DRUG: amg 162

Sponsor

Amgen